Alertness

Caffeine Powder Market to Reach $1,612.1 Million, Globally, by 2032 at 5.5% CAGR: Allied Market Research

Retrieved on: 
Monday, April 8, 2024

WILMINGTON, Del., April 8, 2024 /PRNewswire/ -- Allied Market Research published a report, titled, "Caffeine Powder Market by Source (Synthetic Caffeine, Natural Caffeine), and Application (Food and Beverages, Pharmaceuticals, Cosmetics and Personal Care, Others): Global Opportunity Analysis and Industry Forecast, 2023-2032". According to the report, the "caffeine powder market" was valued at $949.4 million in 2022, and is estimated to reach $1,612.1 million by 2032, growing at a CAGR of 5.5% from 2023 to 2032.

Key Points: 
  • Moreover, caffeine powder offers consumers the flexibility to customize their caffeine intake according to their preferences and needs.
  • In addition, the globalization of the caffeine powder market has led to increased accessibility and availability of products across regions and channels.
  • Furthermore, Europe is home to several prominent pharmaceutical and food industries that utilize caffeine powder in various formulations, further bolstering market growth.
  • With its robust market infrastructure, consumer demand, and regulatory framework, Europe is expected to maintain its leadership position in the global caffeine powder market.

Caffeine Powder Market to Reach $1,612.1 Million, Globally, by 2032 at 5.5% CAGR: Allied Market Research

Retrieved on: 
Monday, April 8, 2024

WILMINGTON, Del., April 8, 2024 /PRNewswire/ -- Allied Market Research published a report, titled, "Caffeine Powder Market by Source (Synthetic Caffeine, Natural Caffeine), and Application (Food and Beverages, Pharmaceuticals, Cosmetics and Personal Care, Others): Global Opportunity Analysis and Industry Forecast, 2023-2032". According to the report, the "caffeine powder market" was valued at $949.4 million in 2022, and is estimated to reach $1,612.1 million by 2032, growing at a CAGR of 5.5% from 2023 to 2032.

Key Points: 
  • Moreover, caffeine powder offers consumers the flexibility to customize their caffeine intake according to their preferences and needs.
  • In addition, the globalization of the caffeine powder market has led to increased accessibility and availability of products across regions and channels.
  • Furthermore, Europe is home to several prominent pharmaceutical and food industries that utilize caffeine powder in various formulations, further bolstering market growth.
  • With its robust market infrastructure, consumer demand, and regulatory framework, Europe is expected to maintain its leadership position in the global caffeine powder market.

Alto Neuroscience Announces Initiation of Phase 2 Study of ALTO-203 in Patients with Major Depressive Disorder

Retrieved on: 
Wednesday, April 3, 2024

Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today announced the initiation of its Phase 2 double-blind, single- and multiple-dose study to determine the pharmacodynamic effects of ALTO-203 in MDD patients as well as assess its safety, tolerability, and pharmacokinetics.

Key Points: 
  • Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today announced the initiation of its Phase 2 double-blind, single- and multiple-dose study to determine the pharmacodynamic effects of ALTO-203 in MDD patients as well as assess its safety, tolerability, and pharmacokinetics.
  • The present study will evaluate these effects in patients with MDD to determine the potential of ALTO-203 as an antidepressant.
  • “In a Phase 1 study, ALTO-203 demonstrated an acute increase in positive emotion relative to placebo and across several dosage levels.
  • This Phase 2 study consists of two sequential double-blind, placebo-controlled treatment periods and examines two doses of ALTO-203 and placebo given as monotherapy in patients with MDD.

Why cocaine is considered performance-enhancing for athletes, and why it matters when the athlete took it

Retrieved on: 
Wednesday, April 3, 2024

Last year a Melbourne Demons player, Joel Smith, and two Sydney Swans AFLW players were caught with cocaine.

Key Points: 
  • Last year a Melbourne Demons player, Joel Smith, and two Sydney Swans AFLW players were caught with cocaine.
  • So how is cocaine considered performance enhancing, and why does it matter when they took it?

What is cocaine and is it performance enhancing?

  • Once consumed, cocaine increases the level of a chemical in the brain called dopamine – a messenger molecular that is associated with pleasure and reward.
  • A surge in dopamine is responsible for feelings of euphoria, heightened energy, and alertness, which makes cocaine highly sought-after for recreational purposes.
  • When used during sport, cocaine is considered to have performance enhancing effects and is prohibited under the World Anti-Doping Code and listed under the Substances of Abuse Category.

Recreational (out of competition) vs performancing-enhancing (in-competition) use

  • As a result, instead of a ban from competing, the court gave them 12-month conditional release orders, with no convictions recorded.
  • Under the AFL’s anti-doping code, a finding of using cocaine for performance enhancement could come with a four-year ban.
  • If he was found to have used it for only recreational purposes, not on game day, the ban would instead just be one or three months.

Can urine testing determine when someone took cocaine?

  • Intact cocaine can remain detectable in urine for periods up to 15 days, and BZE can be detectable up to 25 days.
  • To determine the date of cocaine use, the concentration of intact drug in the athlete’s urine, and possibly the BZE concentration, need to be considered.
  • But there are fundamental flaws in making these comparisons to determine when an athlete took cocaine.

Why is cocaine still considered performance-enhancing?


While it’s unlikely an athlete can genuinely get an athletic edge on their rivals by taking cocaine, it is still on Sports Integrity Australia’s Prohibited List because “all prohibited substances are added to the Prohibited List because they meet two of the three following criteria”:
Athletes really are risking a lot for minimal (if any) athletic reward when they take cocaine – not just the health risks, but the possibility of getting caught with a substance that is extremely unlikely to improve their on-field performances.
Nial Wheate has previously appeared as an expert witness for an athlete accused by Sport Integrity Australia of in-competition cocaine use. Shoohb Alassadi does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.

Gentherm Reports 2023 Fourth Quarter and Full Year Results

Retrieved on: 
Wednesday, February 21, 2024

NORTHVILLE, Mich., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Gentherm (NASDAQ:THRM), the global market leader of innovative thermal management and pneumatic comfort technologies for the automotive industry and a leader in medical patient temperature management systems, today announced its financial results for the fourth quarter and full year ended December 31, 2023.

Key Points: 
  • According to S&P Global’s mid-February 2024 report, actual light vehicle production in the fourth quarter of 2023 increased by 12.8% compared to the fourth quarter of 2022 in the Company’s key markets of North America, Europe, China, Japan and Korea.
  • Selling, general and administrative expenses of $41.9 million in the 2023 fourth quarter increased $5.3 million, or 14.5%, versus the prior year period.
  • Income tax benefit in the 2023 fourth quarter was $0.9 million, as compared with $0.06 million in the prior year period.
  • GAAP diluted earnings per share for the fourth quarter of 2023 was $0.56 compared with a loss of $(0.13) for the prior year period.

ZURZUVAE™ (zuranolone) CIV, a Landmark Oral Treatment for Women with Postpartum Depression (PPD), is Now Available in the U.S.

Retrieved on: 
Thursday, December 14, 2023

CAMBRIDGE, Mass., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Sage Therapeutics, Inc. (Nasdaq: SAGE) announced ZURZUVAE™ (zuranolone) 50 mg (two 25 mg capsules per day) CIV is now available by prescription for the treatment of postpartum depression (PPD) for adults in the United States, with product already at specialty pharmacies and delivered to patients. ZURZUVAE is the first and only oral, 14-day treatment course for adults with PPD that can provide rapid improvements in depressive symptoms at Day 15 and as early as Day 3.

Key Points: 
  • “For women with PPD, delayed improvement in depressive symptoms can significantly worsen outcomes.
  • The program also includes financial assistance, such as a copay assistance program, and product at no cost for eligible patients.
  • The companies are partnering with several of the leading national specialty pharmacies and ZURZUVAE will be shipped directly to women with PPD who are prescribed the treatment.
  • ZURZUVAE is not for use in children
    How can I watch for and try to prevent suicidal thoughts and actions?

Trevena Reports Third Quarter 2023 Results and Provides Business Update

Retrieved on: 
Tuesday, November 14, 2023

ET

Key Points: 
  • ET
    CHESTERBROOK, Pa., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today reported its financial results for the third quarter ended September 30, 2023 and provided an overview of its recent operational highlights.
  • “There is a significant need for safe and effective non-opioid therapies in pain, and for novel mechanisms for the treatment of epilepsy.
  • The Company previously announced preliminary topline data from two Phase 1 proof-of-concept studies evaluating S1PR mechanism of action and CNS target engagement.
  • As part of the R-Bridge Financing, Trevena may receive an additional $10 million upon achievement of either a commercial or financing milestone.

ZURZUVAE™ (zuranolone) CIV, a Landmark Oral Treatment for Women with Postpartum Depression (PPD), is Now Available in the U.S.

Retrieved on: 
Thursday, December 14, 2023

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20231213368658/en/
    “For women with PPD, delayed improvement in depressive symptoms can significantly worsen outcomes.
  • The program also includes financial assistance, such as a copay assistance program, and product at no cost for eligible patients.
  • The companies are partnering with several of the leading national specialty pharmacies and ZURZUVAE will be shipped directly to women with PPD who are prescribed the treatment.
  • ZURZUVAE is not for use in children
    How can I watch for and try to prevent suicidal thoughts and actions?

Safe & Sound Holiday Tips for Seniors According to Lisa M. Cini

Retrieved on: 
Monday, November 27, 2023

Aging expert Lisa M. Cini emphasizes the importance of prioritizing accessibility, functionality, and efficiency for aging loved ones.

Key Points: 
  • Aging expert Lisa M. Cini emphasizes the importance of prioritizing accessibility, functionality, and efficiency for aging loved ones.
  • “The holiday season should be filled with joy, not feelings of sadness or trips to the ER,” says leading aging expert Lisa M. Cini .
  • Safe Holiday Travels: Ensure a smooth journey for aging loved ones by planning ahead.
  • Address potential hazards, secure safe and accessible accommodations, arrange comfortable transportation, and prioritize the senior's health throughout the trip.

The passenger Vehicle Segment is expected to constitute a share of 72.0% in the Automotive AI Chipset Market in 2024 | Future Market Insights, Inc.

Retrieved on: 
Thursday, December 7, 2023

NEWARK, Del., Dec. 7, 2023 /PRNewswire/ -- The global automotive AI chipset market is anticipated to reach a valuation of US$ 3.5 billion in 2024, driven by human-machine interface enhancement. The trend is expected to create new opportunities for the market, leading to a projected CAGR of 22.1% between 2024 and 2034 and reaching a total valuation of approximately US$ 25.9 billion by 2034.

Key Points: 
  • This report, A Comprehensive Analysis of the Automotive AI Chipset Ecosystem, 2034, presents a comprehensive view of this dynamic market, highlighting lucrative opportunities for industry stakeholders.
  • NEWARK, Del., Dec. 7, 2023 /PRNewswire/ -- The global automotive AI chipset market is anticipated to reach a valuation of US$ 3.5 billion in 2024, driven by human-machine interface enhancement.
  • Request Exclusive Sample Report: Automotive AI Chipset Market Strategic Insights: https://www.futuremarketinsights.com/reports/sample/rep-gb-18604
    Two major factors contributing to the market's growth are long-term evolution and 5G connectivity.
  • Future Market Insights offers an unbiased analysis of the global automotive AI chipset market, providing historical data for 2019 to 2023 and forecast statistics from 2024 to 2034.